Jonathan Miller, MD, discusses earlier HPV vaccination, individualized conversations with hesitant families, and strategies to improve vaccine uptake.
|Articles|May 20, 2022
Must-read news from the week of May 16
Author(s)Katie Hobbins
A look at what the Contemporary Pediatrics® team covered this week.
Advertisement
This week’s top articles:
Contemporary Pediatrics® Editorial Advisory Board member Donna Hallas shares her thoughts on the recent authorization of a Pfizer-BioNTech COVID-19 booster shot for children 5-11 years old.
Investigators may have found a piece of the puzzle into what causes sudden infant death syndrome.
This week, the agency announced it is encouraging importation of infant formula from usually unutilized foreign means in hopes of increasing access to the product in the wake of the country-wide shortage.
The proposed aid bill would give the FDA funds to increase staff and prepare for future infant formula shortages.
More articles from this week:
Advertisement
Related to this article
Jonathan Miller, MD, discusses factors behind lagging HPV vaccination rates and how pediatricians can address common parent concerns.
This FAQ breaks down the AAP's newest COVID-19, RSV, and influenza recommendations for clinicians who want a quick refresher on what changed for the 2026-2027 season.
XOCOVA gives pediatricians a new oral option to help prevent COVID-19 after exposure in adolescents aged 12 years and older.
Semaglutide plus lifestyle changes moved 40.4% of children below the obesity threshold at 68 weeks in the phase 3 STEP Young trial.
Five rapid developments — new mRNA flu vaccine, CDC director, ACIP/NVAC charters, a vaccine order, and an HHS RFI — roil the 2026 schedule.
Court fight over CDC 2026 childhood vaccine schedule shifts shots to shared decision-making; experts warn lower uptake for Hep A, B, flu, COVID.
New evidence supports influenza, COVID-19, and RSV immunizations for reducing severe respiratory illness and hospitalization.
Advertisement
Advertisement
Trending on Contemporary Pediatrics
1
FDA grants priority review to leniolisib sNDA for lower-weight children with APDS
2
FDA approves zilurgisertib for fibrodysplasia ossificans progressiva in patients aged 12 years and older
3
FDA approves obinutuzumab to reduce relapse risk in childhood-onset idiopathic nephrotic syndrome
4
First-in-human trial tests microneedle stamp approach for peanut allergy
5